Source link : https://www.newshealth.biz/health-news/more-data-support-olaparib-abiraterone-in-brca-mutant-prostate-cancer/
Combining olaparib (Lynparza) with abiraterone acetate (Zytiga) as first-line therapy for biomarker-selected patients with metastatic castration-resistant prostate cancer significantly improved progression-free survival (PFS) versus either agent alone, according to findings from a small phase II trial presented at this year’s Genitourinary Cancers Symposium. In this exclusive MedPage Today video, Daniel Geynisman, MD, of Fox Chase […]
Author : News Health
Publish date : 2024-02-15 14:43:13
Copyright for syndicated content belongs to the linked Source.